Deciphering the Dynamics of Leukemogenic Transformation from Clonal Hematopoiesis in Congenital Neutropenia
Inherited neutropenia syndromes, severe congenital neutropenia (CN) and Shwachman-Diamond syndrome (SDS), confer a high cumulative risk of MDS and AML. It is not yet clear which somatic mutations, in which combination, allele frequency and sequence identify patients at high risk. We analyzed clonal hematopoiesis (CH) in the largest representative cohort of inherited neutropenia patients to date - 658 samples from 309 patients - using error-corrected panel sequencing with longitudinal sampling. This was complemented in selected cases by single-cell DNA sequencing and genotyping of single-cell derived colonies. CH was detected in early childhood, affecting 37.7% of CN and 60% of SDS patients. The somatic mutation burden remained essentially unchanged over decades. In CN, CSF3R mutations were dominant across genetic subtypes, while additional mutations were rare and included ASXL1, TET2, and DNMT3A. ASXL1 mutations most frequently co-occurred with CSF3R mutations. Co-occurring CSF3R and TP53 mutations were only found in SRP54-CN and CLPB-CN patients. In SDS, TP53 was the most frequently mutated gene, followed by low-prevalence somatic mutations in DNMT3A, IDH1, PTPN11, and RUNX1. In CN-MDS/AML, RUNX1 and SETBP1 mutations emerged shortly before progression to MDS/AML, and membrane-proximal CSF3R mutations only at the leukemic stage. In SDS, biallelic TP53-mutant clones expanded prior to transformation, and a variant allele frequency (VAF) of dominant TP53 clone above 0.074 discriminated between patients who progressed and those who did not. Peripheral blood reflected bone marrow genotype for most key drivers. Leukemic transformation in inherited neutropenia is therefore not stochastic, but rather follows a defined mutational sequence, initiated in childhood.
Authors
- Miriam Erlacher (ORCID: https://orcid.org/0000-0002-7261-1447)
- Karl Welte (ORCID: https://orcid.org/0000-0001-5178-3074)
- Vahagn Makaryan
- Siarhei Kandabarau (ORCID: https://orcid.org/0000-0002-1379-7974)
- David C. Dale (ORCID: https://orcid.org/0000-0002-7146-1440)
- Yvonne Lisa Behrens (ORCID: https://orcid.org/0000-0002-2390-0541)
- Cornelia Zeidler (ORCID: https://orcid.org/0000-0002-8943-0984)
- Merideth L. Kelley
- Torsten Haferlach (ORCID: https://orcid.org/0000-0003-0196-2837)
- Maksim Klimiankou (ORCID: https://orcid.org/0009-0002-9193-0133)
- Julia Skokowa (ORCID: https://orcid.org/0000-0002-4399-2324)
- Markus Mezger (ORCID: https://orcid.org/0000-0002-0211-2343)
- Ayami Yoshimi (ORCID: https://orcid.org/0000-0003-1593-9507)
- Peter Lang (ORCID: https://orcid.org/0000-0001-7737-2142)
- Peter E. Newburger (ORCID: https://orcid.org/0000-0002-8615-673X)
- Niroshan Nadarajah (ORCID: https://orcid.org/0000-0002-6486-9675)
- Sabine Mellor-Heineke (ORCID: https://orcid.org/0009-0000-7467-8058)
- Audrey Anna Bolyard (ORCID: https://orcid.org/0000-0001-5131-1923)
- Claudia Lengerke (ORCID: https://orcid.org/0000-0001-5442-2805)
- Charlotte Marie Niemeyer (ORCID: https://orcid.org/0000-0003-3856-7937)
- Maja Haar
Institutions
- University of Freiburg (DE)
- University of Massachusetts Chan Medical School (US)
- Universität Ulm (DE)
- University of Washington (US)
- University Medical Center Freiburg (DE)
- Medizinische Hochschule Hannover (DE)
- Munich Leukemia Laboratory (Germany) (DE)
- University Children's Hospital Tübingen (DE)
- STZ eyetrial (DE)
- University Hospital Ulm (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-11
- DOI
- https://doi.org/10.64898/2026.11.10.765578
- Primary Topic
- Blood disorders and treatments
- Type
- preprint